From the Institute of Cellular and System Medicine, National Health Research Institutes, Zhunan, Maioli, Taiwan (G.-L.L., C.-C.Y., J.-Y.W., H.-C.L., Y.-F.W., Y.-Y.K., Y.-T.H., C.-C.K.).
Graduate Institutes of Life Sciences, National Defense Medical Center, Taipei, Taiwan (C.-C.Y., Y.-J.H., C.-C.K.).
Arterioscler Thromb Vasc Biol. 2019 Mar;39(3):432-445. doi: 10.1161/ATVBAHA.118.311874.
Objective- Vascular smooth muscle cell (VSMC) transformation to an osteochondrogenic phenotype is an initial step toward arterial calcification, which is highly correlated with cardiovascular disease-related morbidity and mortality. TLR2 (Toll-like receptor 2) plays a pathogenic role in the development of vascular diseases, but its regulation in calcification of arteries and VSMCs remains unclear. We postulate that TLR2-mediated inflammation participates in mediating atherosclerotic arterial calcification and VSMC calcification. Approach and Results- We found that ApoE Tlr2 genotype in mice suppressed high-fat diet-induced atherosclerotic plaques formation during initiation but progressively lost its preventative capacity, compared with ApoE mice. However, TLR2 deficiency prohibited high-fat diet-induced advanced atherosclerotic calcification, chondrogenic metaplasia, and OPG (osteoprotegerin) downregulation in the calcified lesions. Incubation of VSMCs in a calcifying medium revealed that TLR2 agonists significantly increased VSMC calcification and chondrogenic differentiation. Furthermore, TLR2 deficiency suppressed TLR2 agonist-mediated VSMC chondrogenic differentiation and consequent calcification, which were triggered via the concerted actions of IL (interleukin)-6-mediated RANKL (receptor activator of nuclear factor κB ligand) induction and OPG suppression. Inhibition experiments with pharmacological inhibitors demonstrated that IL-6-mediated RANKL induction is signaled by p38 and ERK1/2 (extracellular signal-regulated kinase 1/2) pathways, whereas the OPG is suppressed via NF-κB (nuclear factor κB) dependent signaling mediated by ERK1/2. Conclusions- We concluded that on ligand binding, TLR2 activates p38 and ERK1/2 signaling to selectively modulate the upregulation of IL-6-mediated RANKL and downregulation of OPG. These signaling pathways act in concert to induce chondrogenic transdifferentiation of VSMCs, which in turn leads to vascular calcification during the pathogenesis of atherosclerosis.
目的-血管平滑肌细胞(VSMC)向成骨软骨细胞表型的转化是动脉钙化的初始步骤,而动脉钙化与心血管疾病相关的发病率和死亡率密切相关。TLR2(Toll 样受体 2)在血管疾病的发展中起致病作用,但它在动脉钙化和 VSMC 中的调节作用尚不清楚。我们假设 TLR2 介导的炎症参与介导动脉粥样硬化性动脉钙化和 VSMC 钙化。方法和结果-我们发现,与 ApoE 小鼠相比,载脂蛋白 E(ApoE)Tlr2 基因型的小鼠在启动阶段抑制高脂肪饮食诱导的动脉粥样硬化斑块形成,但逐渐失去其预防能力。然而,TLR2 缺乏可阻止高脂肪饮食诱导的晚期动脉粥样硬化钙化、软骨样化生和钙化病变中 OPG(骨保护素)下调。在钙化培养基中孵育 VSMC 发现,TLR2 激动剂可显著增加 VSMC 钙化和软骨分化。此外,TLR2 缺乏抑制了 TLR2 激动剂介导的 VSMC 软骨样分化和随后的钙化,这是通过 IL(白细胞介素)-6 介导的 RANKL(核因子 κB 配体受体激活剂)诱导和 OPG 抑制的协同作用触发的。用药理学抑制剂进行的抑制实验表明,IL-6 介导的 RANKL 诱导是由 p38 和 ERK1/2(细胞外信号调节激酶 1/2)途径介导的信号,而 OPG 则通过 ERK1/2 介导的 NF-κB(核因子 κB)依赖性信号通路受到抑制。结论-我们得出结论,在配体结合后,TLR2 激活 p38 和 ERK1/2 信号通路,选择性调节 IL-6 介导的 RANKL 的上调和 OPG 的下调。这些信号通路协同作用,诱导 VSMC 的软骨样转化,从而在动脉粥样硬化发病机制中导致血管钙化。